UNIGE document Scientific Article
previous document  unige:138506  next document
add to browser collection
Title

Validation of a commercially available SARS-CoV-2 serological immunoassay

Authors
Zimmer, Gert
show hidden authors show all authors [1 - 19]
Collaboration
Published in Clinical microbiology and infection. 2020
Abstract Objectives: To validate the diagnostic accuracy of a Euroimmun SARS-CoV-2 IgG and IgA immunoassay for COVID-19. Methods: In this unmatched (1:2) case-control validation study, we used sera of 181 laboratory-confirmed SARS-CoV-2 cases and 326 controls collected before SARS-CoV-2 emergence. Diagnostic accuracy of the immunoassay was assessed against a whole spike protein-based recombinant immunofluorescence assay (rIFA) by receiver operating characteristic (ROC) analyses. Discrepant cases between ELISA and rIFA were further tested by pseudo-neutralization assay.
Keywords COVID-19ELISAPseudovirus neutralisation assayRecombinant immunofluorescence assaySARS-CoV-2Serological AssaysSerological testing strategy
Identifiers
PMID: 32603801
Full text
Structures
Research groups Centre de vaccinologie et d'immunologie néonatale (177)
Chimie et protéomique clinique (270)
Emerging viruses (993)
Groupe Laurent Kaiser (virologie clinique) (668)
Citation
(ISO format)
MEYER, Benjamin et al. Validation of a commercially available SARS-CoV-2 serological immunoassay. In: Clinical Microbiology and Infection, 2020. doi: 10.1016/j.cmi.2020.06.024 https://archive-ouverte.unige.ch/unige:138506

309 hits

166 downloads

Update

Deposited on : 2020-07-17

Export document
Format :
Citation style :